Trial Purpose

The primary hypotheses are that coformulated pembrolizumab/vibostolimab is superior to pembrolizumab alone with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by blinded independent central review (BICR), and with respect to overall survival (OS), in participants with non-small cell lung cancer.

Learn More on



When speaking to your doctor, please have the trial identifier number available.

About The Study

All patients who enroll in the trial will receive medication while on the study.

50% of patients will receive pembrolizumab

50% of patients will receive MK-7684A

*You and your study doctor will not know which treatment you are getting.

Trial Phase Icon

Phase 3

Tests the medicine or vaccine in large groups of trial participants (from several hundred to several thousand). For medicines, volunteers have the disease or condition the medicine is designed to treat. In vaccine studies, the volunteers may be healthy or have diseases or conditions. Phase 3 trials take place in hospitals, clinics, or physician offices.

Trial start Icon


  • Actual study start date 7 April 2021
  • Estimated primary completion date 21 April 2026
  • Estimated study completion date 5 June 2028


Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.

Conditions Icon


Lung Neoplasms, Non-Small-Cell Lung Carcinoma

Age Range Icon

Age Range

18 - No Age Maximum

Sex Icon



Trial locations

Locations provided may not reflect the most current site information. Please call the number provided in the location results to confirm.